장의 급성 이식편대숙주병에서 대변미생물무리이식을 시행한 2예
Fecal Microbiota Transplantation for Treating Steroid-Refractory Acute Graft-versus-Host Disease of the Gut
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Restoring the microbiota via fecal microbiota transplantation (FMT) can be an effective treatment for steroid-refractory acute graft-versus-host disease (GVHD) of the gut. Here, we report two adult patients who underwent FMT to treat steroid-refractory acute GVHD of the gut. The first patient was a 43-year-old man who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with cells from a matched sibling donor. The second patient was a 70-year-old woman who underwent haplo-identical HSCT with cells from her son. Gut GVHD developed at 7 and 4 weeks after HSCT, respectively. After undergoing FMT, the clinical symptoms improved; the first patient had a complete response and the second patient had a partial response. Microbial analyses using RNA gene sequencing showed that a diverse fecal microbiome was recovered by 4 weeks after FMT. FMT should be considered an effective therapeutic option for managing steroid-refractory acute GVHD of the gut.
Abstract
Restoring the microbiota via fecal microbiota transplantation (FMT) can be an effective treatment for steroid-refractory acute graft-versus-host disease (GVHD) of the gut. Here, we report two adult patients who underwent FMT to treat steroid-refractory acute GVHD of the gut. The first patient was a 43-year-old man who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with cells from a matched sibling donor. The second patient was a 70-year-old woman who underwent haplo-identical HSCT with cells from her son. Gut GVHD developed at 7 and 4 weeks after HSCT, respectively. After undergoing FMT, the clinical symptoms improved; the first patient had a complete response and the second patient had a partial response. Microbial analyses using RNA gene sequencing showed that a diverse fecal microbiome was recovered by 4 weeks after FMT. FMT should be considered an effective therapeutic option for managing steroid-refractory acute GVHD of the gut.
참고문헌 (12)
- Gooley TA, "Reduced mortality after allogeneic hematopoietic-cell transplantation", N Engl J Med, 363, pp.2091~2101 (2010)
- Dignan FL, "Diagnosis and management of acute graft-versus-host disease", Br J Haematol, 158, pp.30~45 (2012)
- Shono Y, "Gut microbiota injury in allogeneic haematopoietic stem cell transplantation", Nat Rev Cancer, 18, pp.283~295 (2018)
- Kakihana K, "Fecal microbiota transplantation for patients with steroid-resistant acute graftversus-host disease of the gut", Blood, 128, pp.2083~2088 (2016)
- Qi X, "Treating steroid refractory intestinal acute graft-vs.-host disease with fecal microbiota transplantation: a pilot study", Front Immunol, 9, pp.2195~ (2018)
- Przepiorka D, "1994 consensus conference on acute GVHD grading", Bone Marrow Transplant, 15, pp.825~828 (1995)
- Peled JU, "Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation", N Engl J Med, 382, pp.822~834 (2020)
- Stein-Thoeringer CK, "Lactose drives Enterococcus expansion to promote graft-versus-host disease", Science, 366, pp.1143~1149 (2019)
- 신윤지, "재발성 Clostridium difficile 감염 치료로서 대변세균총이식 치료: 현 상황과 지향점", 대한소화기학회지, 69(4), pp.203~205 (2017), 대한소화기학회
- Kaito S, "Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease", Blood Adv, 2, pp.3097~3101 (2018)
- Biernat MM, "Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease : two case reports and a review of the literature", J Int Med Res, 48, pp.300060520925693~ (2020)
- MacMillan ML, "The best endpoint for acute GVHD treatment trials", Blood, 115, pp.5412~5417 (2010)